FDMT Graph | 4D Molecular Therapeutics, Inc.

FDMT Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $3.78M; Research and development (m); Operating expenses $80.81M; Income tax $0.00.
2026-03-31: Revenue $3.05M; Research and development (m); Operating expenses $76.67M; Income tax $0.00.
2025-12-31: Revenue $85.09M*; Research and development (m); Operating expenses $70.38M*; Income tax $0.00*.
2025-09-30: Revenue $90.00K; Research and development (m); Operating expenses $61.27M; Income tax $0.00.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$3.78M	(m)	$80.81M	$0.00	-$72.94M
2026-03-31	$3.05M	(m)	$76.67M	$0.00	-$68.76M
2025-12-31	$85.09M*	(m)	$70.38M*	$0.00*	$19.40M*
2025-09-30	$90.00K	(m)	$61.27M	$0.00	-$56.88M
2025-06-30	$15.00K	(m)	$59.47M	$0.00	-$54.66M
2025-03-31	$14.00K	(m)	$53.63M	$0.00	-$47.97M
2024-09-30	$3.00K	(m)	$51.13M	$0.00	-$43.84M
2024-06-30	$5.00K	(m)	$42.46M	$0.00	-$34.95M
2024-03-31	$28.00K	(m)	$38.16M	$0.00	-$32.40M
2023-09-30	$20.20M	(m)	$34.18M	$0.00	-$10.26M
2023-06-30	$239.00K	(m)	$32.38M	$0.00	-$29.62M
2023-03-31	$298.00K	(m)	$30.40M	(m)	-$28.68M
2022-09-30	$500.00K	(m)	$27.00M	(m)	-$25.69M
2022-06-30	$162.00K	(m)	$28.59M	(m)	-$28.09M
2022-03-31	$1.22M	(m)	$27.61M	(m)	-$26.34M
2021-09-30	$1.37M	$15.84M	$24.03M	(m)	-$22.24M
2021-06-30	$14.58M	$15.22M	$22.18M	(m)	-$7.59M
2021-03-31	$2.00M	$12.77M	$18.31M	(m)	-$16.41M
2020-09-30	$7.42M	$11.55M	$15.24M	(m)	-$7.83M
2020-06-30	(m)	$15.72M	$18.78M	(m)	-$15.15M
2020-03-31	(m)	$13.16M	$16.81M	(m)	-$13.16M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$6.83M	(m)	$157.47M	$0.00	-$141.70M
2025-06-30	$29.00K	(m)	$113.11M	$0.00	-$102.63M
2024-06-30	$33.00K	(m)	$80.63M	$0.00	-$67.35M
2023-06-30	$538.00K	(m)	$62.78M	$0.00	-$58.30M
2022-06-30	$1.38M	(m)	$56.20M	(m)	-$54.42M
2021-06-30	$16.58M	$27.99M	$40.49M	(m)	-$24.00M
2020-06-30	(m)	$28.88M	$35.59M	(m)	-$28.31M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$119.00K	(m)	$174.38M	$0.00	-$159.51M
2024-09-30	$36.00K	(m)	$131.76M	$0.00	-$111.20M
2023-09-30	$20.74M	(m)	$96.96M	$0.00	-$68.55M
2022-09-30	$1.88M	(m)	$83.19M	(m)	-$80.11M
2021-09-30	$17.95M	$43.83M	$64.52M	(m)	-$46.23M
2020-09-30	(m)	$40.43M	$50.83M	(m)	-$36.15M

Revenue and expense 12 month

Period end	Revenue	Operating expenses	Income tax	Net income
2025-12-31	$85.21M	$244.76M	$0.00	-$140.11M
2024-12-31	$37.00K	$187.88M	$0.00	-$160.87M
2023-12-31	$20.72M	$133.59M	$0.00	-$100.84M
2022-12-31	$3.13M	$113.16M	$0.00	-$107.49M
2021-12-31	$18.04M	$89.37M	$0.00	-$71.32M
2020-12-31	(m)	$70.28M	$0.00	-$56.69M
2019-12-31	(m)	$57.75M	(m)	-$49.31M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Solid Biosciences Inc. (SLDB)	United States	$0.802B	-5.07
Aura Biosciences, Inc. (AURA)	United States	$0.639B	-5.61
Attovia Therapeutics, Inc. (ATTO)	United States	$0.828B
Candel Therapeutics, Inc. (CADL)	United States	$0.885B	-8.86
Sana Biotechnology, Inc. (SANA)	United States	$0.886B	-4.92
Allogene Therapeutics, Inc. (ALLO)	United States	$0.574B	-4.33
Prime Medicine, Inc. (PRME)	United States	$0.557B	-3.54
Autolus Therapeutics plc (AUTL)		$0.506B	-1.52
Odyssey Therapeutics, Inc. (ODTX)	United States	$0.960B
Entera Bio Ltd. (ENTX)		$0.485B